EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

MLA

Frustaci, A., et al. Efficacy and Safety of Molto, a Multicenter, Open Label, Phase Ii Clinical Trial Evaluating Venetoclax, Atezolizumab and Obinutuzumab Combination in Richter Syndrome. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1456740074&authtype=sso&custid=ns315887.

APA

Frustaci, A., Montillo, M., Rossi, D., Zinzani, P., Motta, M., Gaidano, G., Quaresmini, G., Scarfò, L., Pietrasanta, D., Coscia, M., Deodato, M., Zamprogna, G., Cairoli, R., Stüssi, G., Zucca, E., Pileri, S., Zenz, T., Tedeschi, A., Frustaci A. M., … Tedeschi A. (2023). Efficacy and Safety of Molto, a Multicenter, Open Label, Phase Ii Clinical Trial Evaluating Venetoclax, Atezolizumab and Obinutuzumab Combination in Richter Syndrome.

Chicago

Frustaci, A, M Montillo, D Rossi, P Zinzani, M Motta, G Gaidano, G Quaresmini, et al. 2023. “Efficacy and Safety of Molto, a Multicenter, Open Label, Phase Ii Clinical Trial Evaluating Venetoclax, Atezolizumab and Obinutuzumab Combination in Richter Syndrome.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1456740074&authtype=sso&custid=ns315887.